Cardiac gene therapy with adeno-associated virus (AAV)-based vectors is emerging as an entirely new platform to treat, or even cure, so far intractable cardiac disorders. This review describes our current knowledge of cardiac AAV gene therapy with a particular focus on the biggest obstacle for the successful translation of cardiac AAV gene therapy into the clinic, namely the efficient delivery of the therapeutic gene to the myocardium.
INTRODUCTION
Cardiac gene therapy with adeno-associated virus (AAV)-based vectors holds great promise for the treatment of both inherited cardiac disorders and acquired cardiac diseases, such as heart failure. At present, for all the inherited diseases and heart failure, the only curative treatment is heart transplant, and for most cardiac illnesses, the currently available symptomatic treatment modalities are inadequate. In contrast, cardiac gene therapy with AAVs has the potential to treat the underlying cause of cardiac diseases and can -at least in principle -be curative, especially for inherited disorders. Here, we discuss the current progress and challenges in cardiac AAV gene therapy with a particular focus on the major obstacle to successful cardiac AAV gene therapy, namely the efficient delivery of the therapeutic transgene to the cardiomyocytes.
BASIC ADENO-ASSOCIATED VIRUS BIOLOGY
AAVs are small, nonenveloped viruses of the parvoviridae family and are generally considered to be nonpathogenic, a highly controversial publication [1] describing a potential link between hepatocellular carcinomas and wild-type AAV notwithstanding.
This lack of pathogenicity might be, at least in part, attributable to the fact that AAV is a defective virus that is unable to replicate on its own. Instead, AAV depends on coinfection with a helpervirus such as adenovirus or herpesvirus [2] .
The genome of AAV is a linear, single-stranded DNA of $4.7 kb in length [flanked by two inverted terminal repeats (ITRs)] that is packaged into an icosahedral capsid composed of 60 capsid proteins.
The genome contains only two genes, Rep and Cap. The Rep gene encodes three proteins that are involved in DNA replication and the packaging of the viral DNA [2] , whereas the Cap gene encodes three capsid proteins (VP1, VP2 and VP3) with overlapping reading frames. A third viral protein, the socalled assembly-activating protein, is translated from an alternative reading frame within the Cap gene [2] . Most importantly for AAV gene therapy, the only cis elements required to produce recombinant AAV vectors (rAAVs) are the ITRs.
What makes rAAVs particularly attractive for cardiac gene therapy is the long-term persistence of the viral genome in an extrachromosomal form, which leads to the durable expression of the therapeutic protein (at least in nondividing cells such as cardiomyocytes) [3] [4] [5] .
INHERITED CARDIOMYOPATHIES
Although a clear classification of inherited cardiomyopathies can be challenging at times because of significant phenotypic overlap, inherited cardiomyopathies are typically classified into five groups: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrythmogenic right ventricular cardiomyopathy (ARVC), restrictive cardiomyopathy and left ventricular (LV) noncompaction cardiomyopathy [6] [7] [8] [9] . Inherited cardiomyopathies are fairly common; the prevalence of HCM alone is estimated be approximately one in 500 [10] , and inherited cardiomyopathies are likely underdiagnosed. The cause of inherited cardiomyopathies, including the more common HCM, DCM and ARVC, is complex with varying penetrance, at times involving multiple mutations and a high prevalence of private mutations [7] [8] [9] . Nonetheless, inherited cardiomyopathies offer a number of attractive targets for AAV gene therapy. Some of the most prominent targets are listed in Table 1. For autosomal recessive cardiomyopathies, or whenever the mutations result in haploinsufficiency, overexpression of the target protein is expected to be sufficient to achieve therapeutic efficacy. On the contrary, for approximately onethird of the genes listed in Table 1 , the size of the respective cDNA exceeds the packaging capacity of AAV, which is $5 kb (including ITRs and regulatory elements [11] ). Consequently, only the smaller cardiomyopathy proteins can be expressed from a single AAV vector. However, with the exception of titin, the overexpression of the other proteins should be feasible with a two AAV vector strategy (reviewed in [11] ). A promising approach to correct mutations in titin is likely gene editing with the CRISPR/CAS9 system [12] . This method has, in fact, been used with some success in a murine model of Duchenne's muscular distrophy [13 & ,14 & ]. It is also noteworthy that allele-specific knockdown of a dominant-negative MYH6 variant with an AAV9 vector resulted in the amelioration of HCM in a mouse model [15 & ]. However, because most mutations causing cardiomyopathies are not the result of the expression of a dominant negative protein, this approach is likely only useful for a small subset of all inherited cardiomyopathies.
Overall, the treatment of inherited cardiomyopathies with AAV gene therapy is conceptually simple and doubtlessly promising. However, in the absence of AAV vectors that efficiently transduce human cardiomyocytes and without suitable large animal models, the translation into the clinic could prove to be challenging.
HEART FAILURE TARGETS
Heart failure is one of the most common causes of morbidity and death in the Western world [16] . Even with the best available treatments, upon diagnosis of heart failure, the 5-year survival rate is only about 50% [16] . However, with our increasing understanding of the biological processes underlying the progression of heart failure, gene therapy has emerged as a promising tool to reverse-specific molecular changes of this devastating disease. Because the potential targets for the treatment of heart failure have been reviewed extensively before, we refer the reader to these publications [17] [18] [19] and provide only a table with promising targets for AAV gene therapy that have been validated in preclinically relevant animal models (Table 2) .
KEY POINTS
Cardiac AAV gene therapy is a novel and promising approach to treat a variety of cardiac disorders for which no satisfactory treatment modalities are available currently.
The efficient delivery of the therapeutic gene to cardiomyocytes is the main roadblock to the successful implementation of cardiac AAV gene therapy.
Currently available AAV vector delivery approaches need to be refined further to optimize cardiomyocyte transduction while minimizing the invasiveness of the procedure.
Above all, novel AAV variants that efficiently transduce human cardiomyocytes and display a reduced sensitivity to preexisting neutralizing antibodies need to be developed.
As can be seen from Table 2 , in preclinically relevant, large animal models the vast majority of cardiac AAV gene therapeutic approaches to treat heart failure have focused on improving calcium handling, which is disturbed in patients with heart failure. Among the targets, the cardiac-specific isoform of the sarcoplasmatic calcium ATPase, SERCA2a, has been the therapeutic protein that has been studied most intensely.
CLINICAL TRIALS
In light of the extensive studies in large animal models, it is not surprising that the first-in-man study of cardiac AAV gene therapy was based on the delivery of SERCA2a with an AAV vector to treat patients with advanced heart failure [41,42 & ]. Phase 1 of the CUPID (calcium upregulation by percutaneous administration of gene therapy in cardiac disease, NCT02346422) was an open-label doseescalation study that enrolled a total of 12 patients [43] . No treatment-related adverse events were observed in this study. Phase 2a was a double-blind randomized placebo-controlled study in 39 patients with three different doses of AAV1 vectors carrying SERCA2a. In this study, the rate of clinical events was significantly lower at the end of the study at 3 years [42 & ]. Based on these promising results, a double-blind, placebo-controlled, multicenter, multinational trial to treat patients with advanced heart failure was designed (CUPID2b trial, NCT01643330, [44] ). In this study, patients with advanced heart failure received either placebo or 10 13 vector genomes of AAV1.SERCA2a. Unfortunately, despite the promising results in phase 1/2a, neither the primary endpoint, time to recurrent cardiac event (heart failure-related hospitalization or ambulatory treatment for worsening heart failure), nor the secondary efficacy endpoint, time to first terminal event (all-cause death, heart transplant or implantation of an LV assist device) showed an improved outcome in treated vs. placebo patients [45 (Table 2 ) and point to potential species differences in AAV1 tropism or deficiency in dosing.
Currently, two trials using a different AAV capsid are being designed. One trial aims to deliver S100A1 with an AAV9 vector, whereas the second trial plans to deliver a constitutively active form of the protein phosphatase 1 inhibitors, I1c, with a chimeric capsid between AAV2 and AAV8 [33, 46] .
ADENO-ASSOCIATED VIRUS TROPISM
Most commonly, recombinant AAVs have capsids that are composed of capsid proteins of the serotypes 1-9. However, additional serotypes and isolates -as well as 'designer variants' [46] -play an increasing role in AAV gene therapy. Collectively, these AAVs have a very broad but distinct tropism. It must be pointed out, however, that despite their distinct tropism none of the currently available AAVs triggers the exclusive expression of the transgene in just one tissue or cell type.
Nonetheless, for the purpose of cardiac gene transfer, three AAV serotypes -AAV1, AAV6 and AAV9 -have emerged as the most promising AAVs. In particular, AAV9 has proven to be the most powerful AAV serotype to transduce efficiently cardiomyocytes in mice and rats when injected systemically [47] .
Unfortunately, our knowledge regarding the cardiac tropism of AAVs in large animals, let alone in humans, is very limited. Moreover, the variety of vector delivery methods used in different studies renders the comparison of the efficiency of cardiac transduction between serotypes difficult, at the best. Further complicating matters is the fact that the numerous research groups studying cardiac gene therapy in clinically relevant large animal studies use different animals; dogs, sheep and pigs being the most commonly used species. Clearly, much work remains to be done to determine what specific roles the AAV serotype/variant, the vector delivery approach and the species play in the tissue distinct expression pattern of AAVs.
NEUTRALIZING ANTIBODIES
AAVs are naturally occurring viruses; hence, it is not surprising that humans can harbor preexisting AAV, adeno-associated virus.
neutralizing antibodies against AAVs (reviewed in [48] ). Because neutralizing antibodies will prevent efficient transduction, the presence of antecedent neutralizing antibodies is a major exclusion criterion in all AAV gene therapy trials. In the only cardiac gene therapy trial, the CUPID trial (NCT02346422 and NCT01643330), the presence of neutralizing antibodies varied according to country and among states in the United States [49] , ranging from a prevalence of 42% in Ohio to a staggering 79% in Poland and Hungary [49] . That nonhuman primates harbor neutralizing antibodies against several AAV serotypes is unsurprising as several AAV serotypes have been isolated from rhesus macaques [50 && ]. But, astonishingly, neutralizing antibodies against the common AAV serotypes are also present in many small and large animal species [51,52 & ,53] . Presumably because of the comparatively high vector doses relative to their weight, preexisting neutralizing antibodies appear not to be an issue in mice. In larger animals, on the other hand, prescreening of the animals for the presence of antecedent neutralizing antibodies is critical.
ADENO-ASSOCIATED VIRUS VECTOR DELIVERY METHODS FOR CARDIAC GENE THERAPY
Delivery of AAV vectors to the myocardium can be broadly divided into two approachesdirect intramyocardial injection and transvascular administration.
Intramyocardial injection
Direct intramyocardial injection has several advantages: the virus can be delivered at a very high local concentration; direct injection bypasses the endothelial barrier, which is a formidable hurdle for efficient gene transfer; off-target organ transduction is minimized, though not eliminated and the neutralizing effect of preexisting antibodies is stunted. But, for global cardiac disorders, such as heart failure and genetically inherited cardiomyopathies, intramyocardial injection is clearly a suboptimal delivery method as the expression of the transgene is restricted to a very small area surrounding the injection site. Nonetheless, for certain applications, for instance for the stimulation of angiogenesis following a myocardial infarction [54] or for the delivery of biological beta-blockers or pacemakers [55, 56] , direct intramyocardial injection might be a desirable approach.
Intramyocardial injection can be done via direct injection after thoracotomy, which offers the greatest flexibility and precision of injection; but this is an invasive technique that is not clinically desirable. Percutaneous, catheter-based injections, on the other hand, are minimally invasive and as such are more desirable from a safety point of view [57] .
Transvascular delivery
Ideally, for most clinical applications, the rAAV could be injected peripherally and trigger the near-homogeneous expression of the therapeutic protein. Unfortunately, this is only readily achievable in rodents but not in large animals, let alone in humans. The reasons for the discrepancy between rodents and large animals and humans are unclear. But the development of AAV vectors that could efficiently transduce human cardiomyocytes upon intravenous injection would offer tremendous therapeutic benefits.
Antegrade intracoronary injection
Antegrade intracoronary infusion of AAV vectors has been used extensively to treat heart failure with AAV gene therapy in large animal models [21 && ,22,32,33] , and percutaneous access to the coronaries is routinely performed during angioplasty. Because of its minimally invasive nature, antegrade intracoronary injection is the only delivery method that has been used to deliver a potentially therapeutic AAV vector clinically [41,42
& ]. However, the published results from the CUPID trial suggest that, at least with AAV1 and a dose of 10 13 vector genomes, this delivery approach results in inefficient delivery of the vector genomes to cardiomyocytes.
To increase the efficiency of delivering SERCA2a to the myocardium, Kaye et al. used a percutaneous cardiac recirculation delivery approach that allows pressure control [24, 58] to deliver AAV1.SERCA2a in a pacing-induced ovine model of heart failure [24] . Strikingly, the SERCA2a overexpression in the highdose (10 13 vector genomes) recirculation group was $29-fold higher than in the group that received 2.5 Â 10 13 vector genomes via intracoronary infusion [24] . This suggests that, at least in an ovine model, antegrade recirculating delivery of rAAV might lead to superior transduction efficiencies when compared with slow antegrade intracoronary delivery.
Retrograde injection
In heart failure, stenotic coronary arteries pose a significant hurdle to the successful delivery of rAAVs via the antegrade route. This barrier to efficient transduction can potentially be overcome by delivery of the vector into the coronary vein. This delivery approach could result in longer dwell times of the vector in the coronary vasculature [59] , increasing the chance of extravasation of the vector. However, to increase gene transfer, a temporary occlusion of the left anterior descending coronary artery, to increase the intravascular pressure, was required [59] . Although this increased vasculature pressure enhances gene transfer, it carries significant clinical risks, especially in patients with advanced heart failure.
Molecular cardiac surgery with recirculating delivery
In a surgical vector delivery technique developed by Bridges et al., the animal is put on cardiopulmonary bypass. This allows the complete isolation of the cardiac circulation from the systemic blood circulation and the recirculation of vector-containing blood exclusively through the cardiac circulation [26 & ]. This system has several advantages: it allows the prolonged circulation of the AAV vector containing the therapeutic transgene through the coronary system, the closed nature of the system might allow its use in patients with preexisting antibodies and off-target transduction is reduced because the system can be flushed from remaining vector before completion of the coronary bypass. Remarkably, 12 weeks after delivering 10 13 vector genomes of AAV1.SERCA2a with the MCARD (molecular cardiac surgery with recirculating delivery) system more than 400 000 vector genomes/mg host DNA could be detected in the myocardium [26 & ]. This compares favorably with the delivery of 2.5 Â 10 13 vector genomes via antegrade intracoronary delivery, which resulted in less than 2000 vector genomes/ mg genomic DNA [24] .
Unfortunately, MCARD is a highly invasive method that is likely only applicable in situations in which an on-pump coronary bypass surgery or valve surgery is required, regardless of vector delivery.
ISOLATION OF VECTORS WITH INCREASED TROPISM FOR CARDIOMYOCYTES AND RESISTANCE TO NEUTRALIZING ANTIBODIES
As has been described above, today no combination of a cardiotropic vector and vector delivery system has been described that allows the efficient transduction of the human myocardium and that is minimally invasive. Hence, intensive efforts by numerous groups are underway to isolate AAV variants with increased tropism for cardiomyocytes and resistance to antecedent neutralizing antibodies. So far, essentially two approaches have been explored: the 'rational design' of novel AAV variants and directed evolution to isolate cardiotropic AAV variants from AAV libraries with diverse capsids. For a review of the directed evolution approaches, we refer to the review by Kotterman and Schaffer [60] .
Using directed evolution, Xiao et al. isolated an AAV variant (M41) that, when tail vein injected into mice, transduced cardiomyocytes with an approximately two-fold lower efficiency when compared with AAV9. Liver transduction, on the other hand, was almost at least 20-fold lower with M41 compared with AAV9 [61 & ]. But, interestingly, in pigs, M41 did not transduce cardiomyocytes efficiently, at least when delivered by antegrade intracoronary infusion (Hajjar, personal communication) pointing to specific differences in AAV tropism. In light of a report by Mark Kay's group showing that AAV8 transduces murine hepatocytes much more efficiently than human hepatocytes [62 & ], speciesspecific differences in tropism are of significant concern.
Asokan et al. [46] followed a 'rational design' approach to isolate AAV variants with cardiac tropism. Specifically, they replaced a hexapeptide in the receptor-binding region of AAV2 with the corresponding hexapeptides of seven other serotypes [46] . When they swapped the hexapeptide of AAV2 with the corresponding peptide of AAV8, the resulting vector (AAV2i8) displayed broad muscle tropism and efficiently transduced the myocardium. Moreover, liver transduction by AAV2i8 was drastically reduced when compared with AAV2 and AAV8 [46] . Using AAV2i8 (a.k.a. BNP116), Fish et al. demonstrated that delivery of a constitutively active inhibitor of protein phosphatase 1, I1c and ameliorated heart failure symptoms in a porcine MI model of heart failure [32] . Based on these promising results, a phase 1/2 trial is currently being designed.
CONCLUSION
Gene therapy with AAVs shows great promise for the treatment of numerous inherited and acquired cardiovascular diseases. However, the efficient delivery of the therapeutic payload to human cardiomyocytes -and other target cells of the cardiovascular system, for this matter -remains a formidable roadblock to realize the great potential of cardiac AAV gene therapy. Both refined delivery methods and, even more importantly, improved AAV vectors will be essential to bring cardiac AAV gene therapy to the clinic. 
